Clinical Trial Search

Primary: Change From Baseline in Plasma Human Immunodeficiency Virus-1 (HIV-1) Ribonucleic Acid (RNA) at Day 11 — 0.05; -1.51; -2.03; -2.46 Log10 copies/milliliter (log10…

Primary: Number of Participants Who Achieved HIV-1 RNA <400 Copies (c)/Milliliter (mL) or at Least 0.7 log10 c/mL Below Their Baseline Value at Day 11 — 21; 23 Participants

Primary: Change in Normalized Composite Neurocognitive Test Score at Week 48 From Baseline — 0.20; 0.26; 0.31 total neurocognitive z-score — p=0.60

Primary: Mean Change From Baseline Plasma HIV RNA (Log Copies/mL) — 5.4 log copies/mL plasma

Primary: Number of Treatment-naïve Participants With Human Immunodeficiency Virus Ribonucleic Acid (HIV-RNA) Levels Less Than (<)50 Copies/Milliliter (c/mL) at 24 Weeks After 2DR…

Primary: Number of Patients Virologically Suppressed (HIV RNA <50 Copies/ml) at 48 Weeks. — 5 Participants

Primary: Proportion of Patients Who Maintain Plasma HIV Viral Load Measurements < 400 Copies/ml at 2, 4, 8, 12, 16, 24, 36 and 48 Weeks After Switching to DRV/r and ETR, Missing…

Primary: Percentage of Participants With HIV-1 Ribonucleic Acid (RNA) <50 Copies/Milliliter (c/mL) at Week 48 — 71; 64 Percentage of participants — p=0.030

Primary: Percentage of Participants With Plasma HIV-1 Ribonucleic Acid (RNA) < 50 Copies Per Milliliter (c/mL) at Week 24 — 80; 69; 76; 72 Percentage of Participants

Primary: HIV-1 RNA Level — 1.2; 1.7 copies/mL — p=0.546

Primary: Prevalence of Adverse Events (Weeks 0-144), Per Event — 13.8; 19.3; 1.0; 4.4 percentage of adverse events

Primary: Difference in Proportion With Failure (Clinical or Virological) — 0; 3; 0; 0 Participants — p== 0.004

Primary: Proportion of Participants With Treatment Failure — 0.0682; 0.0667 proportion of participants

Primary: Percentage of Participants With Grade 3 or 4 Adverse Events (AEs) — 20.3; 25; 15.4; 30 percentage of participants

Primary: Rectal Tissue Concentrations of Ralegravir and Dolutegravir — 5308; 810 ng/g — p=1.0

Primary: Treatment Response at Week 48 — 34.5; 15 percentage of participants — p=0.0001

Primary: Change in Proviral HIV-1 DNA in Total CD4+ T-cells From Baseline to Week 48 in Participants Randomized to the Intensified Arm Versus the Control Arm Who Received Placebo…

Primary: Changes in the Inflammatory Marker IL-6 — 42.5; 40.0; 39.3; 41.1 pg/mL

Primary: Number of Participants in Each Group (Study Drug vs. Placebo) With Undetectable Plasma HIV-1 RNA, as Measured by an Ultra-sensitive Assay With a Limit of Detection of 1…

Primary: Doravirine Maximum Concentration (Cmax) — 1.7; 1.3 ug/mL

Primary: Number of Participants With Human Immunodeficiency Virus Type 1 (HIV-1) Ribonucleic Acid (RNA) Viral Load <50 Copies/mL — 79; 78 participants

Primary: Percentage of Participants With HIV-1 RNA Level <40 c/mL at Week 24 — 80.6; 94.6 Percentage of participants

Primary: Viral Load — 4 Participants

Primary: Geometric Mean of C-Trough, of Raltegravir (RAL) at a Dose of 400 mg Twice a Day Plus Darunavir/Ritonavir (DRV/RTV) at a Dose of 800/100 mg Once a Day in HIV-1-infected…

Primary: Mean Change From Baseline in Plasma Human Immunodeficiency Virus Type 1 (HIV-1) Ribonucleic Acid (RNA) at Day 8 — -1.06; 0.10 Log 10 copies per milliliter (c/mL)…

Primary: CD4+ T-cell Count — 602; 648; 689; 750 cells/µL — p=>0.05

Primary: Treatment Failure — 49; 70; 48; 69 Participants

Primary: Change From Baseline in CD4 Count at 48 Weeks — 192; 205 cells/uL

Primary: Mean Change From Baseline in Plasma HIV-1 RNA at Day 8 — -1.432 log10 copies/milliliter (mL) — p=<0.001

Primary: Inflammatory Biomarker 1: Plasma hsCRP Concentration — 3.4; 5.4; 2.9; 7.4 mg/L — p=0.006